The findings of our study have significant clinical implications for identifying patients who have an adverse response to frontline chemotherapy and provide a novel reference for further prognostic stratification of NPM1mut/FLT3‐ITDwt AML patients. Here, FLT3 is linked to acute myeloid leukemia.